Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1982 1
1983 2
1985 1
1986 1
1989 1
1991 1
1992 1
1993 1
1994 2
1995 2
1996 1
1997 4
1998 6
1999 10
2000 9
2001 26
2002 24
2003 53
2004 69
2005 69
2006 89
2007 112
2008 105
2009 136
2010 130
2011 119
2012 138
2013 155
2014 195
2015 210
2016 196
2017 231
2018 262
2019 279
2020 331
2021 360
2022 348
2023 334
2024 182

Text availability

Article attribute

Article type

Publication date

Search Results

3,773 results

Results by year

Filters applied: . Clear all
Page 1
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J, Tho LM, Xu N, Gillespie DA. Smith J, et al. Adv Cancer Res. 2010;108:73-112. doi: 10.1016/B978-0-12-380888-2.00003-0. Adv Cancer Res. 2010. PMID: 21034966 Review.
DNA damage is a key factor both in the evolution and treatment of cancer. Genomic instability is a common feature of cancer cells, fuelling accumulation of oncogenic mutations, while radiation and diverse genotoxic agents remain important, if imperfect, therapeutic …
DNA damage is a key factor both in the evolution and treatment of cancer. Genomic instability is a common feature of cancer ce …
Targeting ATR in cancer.
Lecona E, Fernandez-Capetillo O. Lecona E, et al. Nat Rev Cancer. 2018 Sep;18(9):586-595. doi: 10.1038/s41568-018-0034-3. Nat Rev Cancer. 2018. PMID: 29899559 Review.
The chemical treatment of cancer started with the realization that DNA damaging agents such as mustard gas present notable antitumoural properties. ...A refinement to this approach is to use compounds that can exploit the presence of DNA damage in cancer cells. Give …
The chemical treatment of cancer started with the realization that DNA damaging agents such as mustard gas present notable antitumour …
Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic.
Priya B, Ravi S, Kirubakaran S. Priya B, et al. Drug Discov Today. 2023 Aug;28(8):103662. doi: 10.1016/j.drudis.2023.103662. Epub 2023 Jun 10. Drug Discov Today. 2023. PMID: 37302542 Review.
Cancer cells have a high DSB burden, and therefore rely on DSB repair for survival. Therefore, targeting DSB repair can sensitize cancer cells to DNA-damaging agents. This review focuses on ATM and ATR, their roles in DNA damage and repair pathways, challenge …
Cancer cells have a high DSB burden, and therefore rely on DSB repair for survival. Therefore, targeting DSB repair can sensitize …
Emerging strategies for cancer therapy by ATR inhibitors.
Yano K, Shiotani B. Yano K, et al. Cancer Sci. 2023 Jul;114(7):2709-2721. doi: 10.1111/cas.15845. Epub 2023 May 15. Cancer Sci. 2023. PMID: 37189251 Free PMC article. Review.
DNA replication stress (RS) causes genomic instability and vulnerability in cancer cells. To counteract RS, cells have evolved various mechanisms involving the ATR kinase signaling pathway, which regulates origin firing, cell cycle checkpoints, and fork stabilizatio …
DNA replication stress (RS) causes genomic instability and vulnerability in cancer cells. To counteract RS, cells have evolved variou …
Targeting ATR in patients with cancer.
Ngoi NYL, Pilié PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Ngoi NYL, et al. Nat Rev Clin Oncol. 2024 Apr;21(4):278-293. doi: 10.1038/s41571-024-00863-5. Epub 2024 Feb 20. Nat Rev Clin Oncol. 2024. PMID: 38378898 Review.
Multiple novel, potent ATR inhibitors are being tested in clinical trials using biomarker-directed approaches and involving patients across a broad range of solid cancer types; some of these inhibitors have now entered phase III trials. ...In this Review, we detail …
Multiple novel, potent ATR inhibitors are being tested in clinical trials using biomarker-directed approaches and involving patients …
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
Gupta N, Huang TT, Horibata S, Lee JM. Gupta N, et al. Pharmacol Res. 2022 Apr;178:106162. doi: 10.1016/j.phrs.2022.106162. Epub 2022 Mar 5. Pharmacol Res. 2022. PMID: 35259479 Free PMC article. Review.
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have become a mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant breast, prostate, and pancreatic cancers. ...Inhibitors of these cell cycle checkpoints are under investigation …
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have become a mainstay of therapy in ovarian cancer and other malignancies, i …
DNA repair defects in cancer and therapeutic opportunities.
Hopkins JL, Lan L, Zou L. Hopkins JL, et al. Genes Dev. 2022 Mar 1;36(5-6):278-293. doi: 10.1101/gad.349431.122. Genes Dev. 2022. PMID: 35318271 Free PMC article. Review.
Defects of DNA repair and damage signaling contribute to tumorigenesis, but also render cancer cells vulnerable to DNA damage and reliant on remaining repair and signaling activities. ...Furthermore, we discuss the impacts of DNA repair defects on both targeted therapy and …
Defects of DNA repair and damage signaling contribute to tumorigenesis, but also render cancer cells vulnerable to DNA damage and rel …
Targeting replication stress in cancer therapy.
da Costa AABA, Chowdhury D, Shapiro GI, D'Andrea AD, Konstantinopoulos PA. da Costa AABA, et al. Nat Rev Drug Discov. 2023 Jan;22(1):38-58. doi: 10.1038/s41573-022-00558-5. Epub 2022 Oct 6. Nat Rev Drug Discov. 2023. PMID: 36202931 Free PMC article. Review.
Replication stress is a major cause of genomic instability and a crucial vulnerability of cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that coordinate the DNA damage response with cell cycle control, including ATR, CHK1, WEE …
Replication stress is a major cause of genomic instability and a crucial vulnerability of cancer cells. This vulnerability can be the …
Targeting ARID1A mutations in cancer.
Mullen J, Kato S, Sicklick JK, Kurzrock R. Mullen J, et al. Cancer Treat Rev. 2021 Nov;100:102287. doi: 10.1016/j.ctrv.2021.102287. Epub 2021 Sep 6. Cancer Treat Rev. 2021. PMID: 34619527 Review.
It is the most commonly mutated member of the SWI/SNF complex, being aberrant in 6% of cancers overall, including ovarian clear cell cancers (45% of patients) and uterine endometrioid cancers (37%). ...A variety of compounds may be of benefit in ARID1A-altere …
It is the most commonly mutated member of the SWI/SNF complex, being aberrant in 6% of cancers overall, including ovarian clear cell …
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.
Blackford AN, Jackson SP. Blackford AN, et al. Mol Cell. 2017 Jun 15;66(6):801-817. doi: 10.1016/j.molcel.2017.05.015. Mol Cell. 2017. PMID: 28622525 Free article. Review.
In vertebrate cells, the DNA damage response is controlled by three related kinases: ATM, ATR, and DNA-PK. It has been 20 years since the cloning of ATR, the last of the three to be identified. ...We also highlight what is known regarding their structural similariti …
In vertebrate cells, the DNA damage response is controlled by three related kinases: ATM, ATR, and DNA-PK. It has been 20 years since …
3,773 results